1.	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
2.	Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: CDR0000732604, COG-ANHL1131, ANHL1131, NCT01595048
3.	Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 1 to under 30 Sponsor: NCI, Other Protocol IDs: AALL0433, COG-AALL0433, CDR0000495359, NCT00381680
4.	Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and under at diagnosis Sponsor: NCI, Other Protocol IDs: CDR0000573996, COG-AALL0631, AALL0631, NCT00557193
5.	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, NCT00549848
6.	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
7.	Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 1 to < 10 Sponsor: NCI, Other Protocol IDs: CDR0000683227, COG-AALL0932, AALL0932, NCT01190930
8.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
9.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000706370, COG-AALL1131, AALL1131, NCT01406756
10.	Phase III Randomized Study of Adherence to Maintenance Mercaptopurine Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia in First Remission Phase: Phase III Type: Educational/Counseling/Training, Treatment Status: Active Age: 12 to 25 Sponsor: NCI Protocol IDs: COG-ACCL1033, ACCL1033, NCT01503632
11.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Phase: Phase III Type: Behavioral study, Treatment Status: Active Age: 1 to under 31 Sponsor: NCI Protocol IDs: NCI-2009-00307, AALL0434, CDR0000514500, COG-AALL0434, U01CA98543, NCT00408005
12.	Phase I/II Pilot Study of Non-Myeloablative Chemotherapy Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Hematopoietic Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 4 to 21 Sponsor: NCI Protocol IDs: NCI-01-C-0125F, NCT00020592
13.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
14.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
15.	Reduced Intensity Transplant Using Extracorporeal Photopheresis Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Pharmaceutical / Industry Protocol IDs: ECP RIT, NCT00179790
16.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514
17.	Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL Phase: Phase II, Phase I Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: L 9471, NCT00529360
18.	Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 6 to 50 Sponsor: NCI, Other Protocol IDs: 05021, P30CA033572, CHNMC-05021, CDR0000579141, NCI-2010-00427, NCT00576979
19.	Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
20.	Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 25 and under Sponsor: Other Protocol IDs: BMT06407, H-2006-0297, 2012-0661, NCT00582816
21.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
22.	CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 80 and under Sponsor: Other Protocol IDs: 23637-MULTIPRAT, MultiPRAT, NCT00840853
23.	A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 months to 18 years Sponsor: Pharmaceutical / Industry Protocol IDs: CPKC412A2114, 2008-006931-11, NCT00866281
24.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
25.	Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 21 Sponsor: Other Protocol IDs: T2008-002, NCT00981799